AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01920841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cream A applied to left thigh and Cream B to right thigh
Description: Half the participants will receive Cream A applied to the left thigh, and Cream B applied to the right thigh
Study NCT01920841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cream B applied to left thigh and Cream A to right thigh
Description: Half the participants will receive Cream B applied to the left thigh and Cream A applied to the right thigh
Study NCT04261153 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive stimulation
Description: 3 cognitive stimulation sessions in total from the HAPPYNeuron® software, approximately 20 minutes each and spread over several days
Study NCT03542929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration
Description: whole body vibration training on a vibrating platform with healthy elderly and diabetic elderly
Study NCT03542929 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: whole body vibration
Description: whole body vibration training on a vibrating platform with healthy elderly and diabetic elderly
Study NCT02874820 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]BU99008
Description: Baseline and blocked scans
Study NCT02874820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idazoxan
Description: Idazoxan dose up to 80mg
Study NCT02145949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential Amino Acids (EAA)
Description: Twice daily ingestion of 20 or 23 grams of EAA for 7 days leading up to surgery and continuing for 6 weeks after surgery \[surgery = primary total knee arthroplasty\]
Study NCT02145949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Alanine)
Description: Twice daily ingestion of 20 or 23 grams Placebo (alanine) for 7 days leading up to surgery and continuing for 6 weeks after surgery \[surgery = primary total knee arthroplasty\]
Study NCT02959398 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard mammography
Description: Standard mammography
Study NCT02959398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard mammography and tomosynthesis
Description: Standard mammography and tomosynthesis
Study NCT02393066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Sedation
Study NCT02393066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Sedation
Study NCT02867748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TVT-Abbrevo
Study NCT02867748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serasis
Study NCT00995462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention seminars
Description: The first sessions emphasize acquisition of new knowledge during interactive group seminars designed to maximize attendant's participation by adapting wellknown quiz-show or parlour games to deliver key concepts. A number of sessions are aimed at increasing self-efficacy through problem-solving, time-management strategies, individual self monitoring and goal-setting.During the second year, the intervention focuses on maintenance of healthy behaviour with empowerment of the participants using problem-solving, goal-setting, planning, and self-monitoring skills.
Study NCT00787410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD1839
Description: 250mg tablet, once daily, orally administered
Study NCT00385970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur-uracil (UFT)
Description: From within 9 weeks after surgery, 300 mg/m2, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
Study NCT00385970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-uracil (UFT)
Description: From within 9 weeks after surgery, 300 mg/m2, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
Study NCT00385970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium folinate (LV)
Description: From within 9 weeks after surgery, 75 mg, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
Study NCT00385970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Krestin (PSK)
Description: From within 9 weeks after surgery to 12 months after surgery, 3 g/day, PO every day
Study NCT00572650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vildagliptin
Description: 16 volunteers in each group of mild renal impairment patients and their matched healthy volunteers will receive once daily doses of 100mg LAF237 for 14 days.
Study NCT01745029 — intervention group
Intervention type: DEVICE
Intervention: Motilis-3D-transit
Study NCT03683381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Health
Description: Participants in the intervention group will be provided with an application containing weekly instructions to improve sleep
Study NCT03683381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Participants in the Patient education group will receive weekly information on insomnia symptoms
Study NCT00110266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: 20 mg/kg/day over one year in patients with MDS
Study NCT01305460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Treatment will consist of azacitidine 75mg/m2/d for 5 days every 14 days for 4 cycles.~* Patients achieving CR or PR will be then treated with 4 cycles of azacitidine 75mg/m2/d for 5 days every 21 days followed by cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 9 and beyond), to be continued until progression/relapse or toxicity arises.~* Patients not obtaining CR or PR after the initial 4 cycles of azacitidine-14 will continue to receive azacitidine 75mg/m2/d for 5 days every 14 days for 4 additional cycles (cycles 5 to 8). If they achieve CR, PR or HI after 8 cycles, they will then be treated with azacitidine 75mg/m2/d for 5 days every 21 days (cycles 9 to 12) and subsequently cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 13 and beyond) until progression/relapse or toxicity arises.~* Patients not obtaining CR, PR or HI after 8 cycles of azacitidine-14 will go off-study.
Study NCT03340246 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed sclerotherapy
Description: See arm descriptions
Study NCT03340246 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate phlebectomy
Description: See arm description
Study NCT01924572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cord clamping at 2 minutes
Study NCT01924572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cord clamping at 5 minutes
Study NCT01924572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cord milking
Study NCT02586909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-101 35 mg tablets
Description: once daily, oral tablets
Study NCT01456598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Description: * After laparoscopic observation, the possibility of surgery can be considered by examining inside of abdomen.~* The surgeon undergoes laparoscopic subtotal gastrectomy and D2 lymph node dissection~* After lymph node dissection, it is possible to undergo gastrectomy on appropriate part and reconstruction under small incision or laparoscopic view.~* As the reconstruction, one of the techniques like Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance.
Study NCT01456598 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open gastrectomy
Description: * After laparotomy, the possibility of surgery can be considered by examining inside of abdomen.~* The surgeon undergoes open subtotal gastrectomy and D2 lymph node dissection~* After lymph node dissection, one of the techniques likes Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance.
Study NCT01778296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the neurocutaneous island flap
Description: The neurocutaneous island flap of the dorsal branch of the digital nerve can be used for repair the defects of the proximal and middle phalanxes of adjacent fingers.
Study NCT01613066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrabone Allogeneic Transplant
Description: Unrelated single unit intrabone cord blood transplantation
Study NCT03992456 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV
Study NCT03992456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03992456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03992456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03992456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03992456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Given PO
Study NCT03992456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given PO
Study NCT01832896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecallantide subcutaneous dosing
Description: For acute attacks of Hereditary Angioedema in children and adolescents, Ecallantide will be administered.
Study NCT03953391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tea
Description: Subjects walk to a nearby area and prepare a cup of 150 ml tea once every hour. The tea is consumed whilst being seated at their desks.
Study NCT03953391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: 150 ml water is served to subjects once every hour. The water is consumed whilst being seated at their desks.
Study NCT03253809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotronik Vision Guidewire
Description: The apical, mid ventricular and basal sites within the anterior,posterior and lateral coronary sinus branch veins will be paced.
Study NCT02943369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose
Description: Ticagrelor 180 mg
Study NCT02943369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 180 mg loading dose
Description: Ticagrelor 180 mg
Study NCT02943369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min
Description: Intravenous Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min for 2 hours
Study NCT00326339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R788
Description: R788 50 mg, 100 mg, or 150 mg PO bid
Study NCT00326339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo PO bid
Study NCT03672201 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Pharmacological Intervention
Description: The behavioural intervention will be a structured implementation of individualized activities to be followed and customized as per the needs of the participant.
Study NCT03672201 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Intervention
Description: The medication algorithm provides recommendations to the treatment team about algorithmic treatment and assessments as per the ICP but ultimately the decision to prescribe any particular intervention will be the treatment team's decision and the recommendations of the research team for ICP arm will not be binding for the treatment team.
Study NCT02187406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified ankle athletic taping
Study NCT02187406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional ankle athletic taping
Study NCT02238639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic and therapeutic strategy: Highly sensitive D-dimer testing and, if positive, multidetector computed tomographic pulmonary angiography (MDCT).
Description: If MDCT is positive for pulmonary embolism, patients will receive anticoagulant treatment according to updated guidelines.~If MDCT is negative for pulmonary embolism, patients will receive standard management for their exacerbation.
Study NCT01231880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Four monthly IPT with dihydroartemisinin Piperaquine (DP)
Description: Given every 4 months (once a school term)
Study NCT01231880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monthly IPT using DP
Description: Given every month
Study NCT01231880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo given every month
Description: No active ingredient
Study NCT04162301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS3002
Description: CS3002 tablet will be orally administered daily for 3 weeks followed by 1 week off treatment, defining a treatment cycle of 28 days in duration.
Study NCT04240665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Memory Notebook (DMN) Application
Description: Subjects will be taught to utilize the DMN application through 2-hour weekly sessions for 6-weeks.
Study NCT01771627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: Given PO
Study NCT01771627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patch
Study NCT03022799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KM-819
Study NCT03022799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04074109 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Teleyoga
Description: the yoga protocol will be delivered via a tablet computer to groups of participants
Study NCT04074109 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person yoga
Description: the yoga protocol will be delivered by a yoga instructor in the room to group of participants
Study NCT04613310 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Rapid Diagnostic Test vs PCR
Description: 4 swabs taken, saliva for PCR and RDT, nasopharyngeal for PCR and RDT
Study NCT03185949 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Endobar Infusion Catheter System
Description: Bariatric embolization with microspheres using Endobar Infusion Catheter System
Study NCT03185949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobar Infusion Catheter System
Description: Bariatric embolization with microspheres using Endobar Infusion Catheter System
Study NCT03185949 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Behavioral therapy
Description: Healthy diet and exercise
Study NCT03185949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Description: Healthy diet and exercise
Study NCT02701049 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Methods to collect SO/GI information in the ED
Description: In Mode 1, all patients presenting to the ED will have SO/GI information collected verbally by the nurse, which is standard of care. In Mode 2, all patients presenting to the ED will have SO/GI information collected in a non-verbal manner, in which the registrar will ask them to complete an electronic form.
Study NCT03889405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVU™
Description: The subject will undergo continuous recording of the uterine contractions and the fetal heart rate (FHR) for 30 to 60 min using INVU™.
Study NCT03889405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IUPC
Description: The study participants will undergo continuous recording of the uterine contractions by IUPC.
Study NCT03889405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOCO
Description: Some of the study participants will undergo continuous recording of the uterine contractions and the fetal heart rate (FHR) by TOCO as well.
Study NCT02388659 — intervention group
Intervention type: DEVICE
Intervention: 3 Tesla scanning
Description: Approximately 38 brain tumor patients with IDH mutated gliomas and 50 patients with non-glioma disease will be scanned.
Study NCT01830257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sending message
Description: Sending the suggestive short message
Study NCT04905238 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: Continuous positive airway pressure
Study NCT02149277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: The fertility specialist will inject the study medication or its placebo on the 6th day of gonadotrophin stimulation for IVF subjects. For the subjects undergoing embryo transfer, the injection will be done once the endometrial lining measure more than 8mm.
Study NCT02149277 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Filgrastim
Description: The fertility specialist will inject the study medication or its placebo on the 6th day of gonadotrophin stimulation for IVF subjects. For the subjects undergoing embryo transfer, the injection will be done once the endometrial lining measure more than 8mm.
Study NCT00672308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benefiber
Study NCT00672308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benefiber with ORS
Description: Benefiber (50 g/L)-supplemented, reduced-osmolarity WHO-ORS
Study NCT00672308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benefiber with ORS
Study NCT00672308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the reduced-osmolarity WHO-ORS without added Benefiber
Study NCT00658086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN-RSV01
Description: administered by nebulization once daily for 3 days
Study NCT00658086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: administered by nebulization once daily for 3 days
Study NCT01004575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: implantation of Kaname Cobalt-Chromium coronary stent
Description: implantation of Kaname Cobalt-Chromium coronary stent
Study NCT00057330 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine
Description: the vaccine was administered intramuscularly in the non-dominant deltoid
Study NCT00057330 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine
Description: the vaccine was administered intramuscularly in the non-dominant deltoid
Study NCT03009591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Longitudinal surface sliding maneuver over the superficial fascia in the anterior region of the arm and the forearm. Applied in 3 strokes.~* Transverse sliding of the flexor muscles of the wrist and fingers.~* Transverse sliding for the biceps brachii muscle.~* Longitudinal surface sliding over the superficial fascia in the posterior arm region.~* Transverse sliding over the brachial triceps tendon.~* Transverse sliding for the pectoralis major muscle.~* Transverse sliding for the posterior axillary region pectoralis major muscle.~* Induction of the posterior axillary fold.~* Induction (crossed hands over the brachial region and forearm).~* Maneuver of transverse planes for the cervicothoracic region.~* Upper limb telescopic maneuver.
Study NCT03145038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed
Description: Vericiguat high-dose pediatric formulation (fed; American breakfast), 10 mg given as 20 x 0.5 mg mini tablets
Study NCT03145038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted
Description: Vericiguat high-dose pediatric formulation (fasted),10 mg given as 20 x 0.5 mg mini tablets
Study NCT03145038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed
Description: Vericiguat low-dose pediatric-formulation (fed; American breakfast), 2.5 mg given as 25 x 0.1 mg mini tablets
Study NCT03145038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;American breakfast
Description: 10 mg IR tablet, intact (fed; American breakfast)
Study NCT03145038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed;American breakfast
Description: 10 mg IR tablet, crushed (fed; American breakfast)
Study NCT03145038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;Continental breakfast
Description: 10 mg IR tablet, intact (fed; Continental breakfast)
Study NCT00094900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-1 Trap
Study NCT00817427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controls Short sleep
Description: Healthy control subject's bedtime will be decreased by 2 hours/night with acoustic sleep disruption